Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty.
J Nutr Health Aging
; 28(8): 100315, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-39025017
ABSTRACT
OBJECTIVES:
Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric populationDESIGN:
Prospective, randomized, open-labeled.SETTING:
Siriraj Hospital, Thailand.PARTICIPANTS:
Geriatric adults aged ≥65 years. INTERVENTION 10 µg intradermal or 30 µg intramuscular BNT162b2 (Pfizer-BioNTech). MEASUREMENTS Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants' Clinical Frailty Scale.RESULTS:
A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.CONCLUSION:
Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs. REGISTRATION OF CLINICAL TRIALS The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunogenicidade da Vacina
/
Vacinas contra COVID-19
/
COVID-19
/
Vacina BNT162
País/Região como assunto:
Asia
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article